CDNA
$37.94
Caredx
$1.06
2.87%
CDNA
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.23)
Revenue:  $45.45 Mil
Tuesday
Nov 3
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Tuesday, August 4, 2020

What do you expect when CDNA reports earnings?
Beat
Meet
Miss

Where is CDNA's stock price going from here?
Up
Flat
Down
Stock chart of CDNA
Analysts
Summary of analysts' recommendations for CDNA
Score
Grade
Pivots
Resistance
$40.61
$39.64
$38.79

$37.82

Support
$36.97
$36.00
$35.15
Tweet
Growth
Description
CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA (cfDNA) as a biomarker for rejection. CareDx, Inc. is based in Brisbane, California.
Peers
Myriad GeneticsImmunomedicsQuidelMeridian BioscienceSurModics